Lumithera – Possible Treatment for Dry Macular Degeneration

August 26, 2014

Researchers have been exploring the potential of laser light therapy in a number of disease states for quite a while.


Poulsbo, Washington startup LumiThera is developing an LED light-based instrument, for use in an ophthalmologist’s office, to treat the dry form of acute macular degeneration. The company uses low-level light therapy, or LLLT, in which patients are exposed to low-level laser lights to stimulate cellular function.

LumiThera says patients with dry acute macular degeneration have improved eyesight in its pilot clinical study with low-level laser therapy, with up to one year follow-up. It is raising $3 million to expand this technology, according to a regulatory filing. Thus far, it has raised $325,000

Read more:


Pilot Study on ChromaGen Lenses helping with reading problems

August 26, 2014

We have a Life Changing Optical Lens Solution that Treats Reading Disorders that Changes Lives!

Pilot Study on ChromaGen Lenses 

ChromaGen Lenses help those struggling with reading problems such as dyslexia by using selective wavelengths of light to dynamically balance the speed of information as it travels from the eye, through the optic nerve to the patient’s brain. They look like regular eyeglasses with tinted lenses.

Once the appropriate ChromaGen Lenses are prescribed for each eye, unruly words and sentences are brought into focus. Our patients describe that the words “are standing still for the first time”.  In addition to seeing improvements in reading and handwriting, our patients also report a significant reduction in headaches, nausea and fatigue while reading or working on the computer.

Recently Clear Solutions for Reading LLC completed a Pilot Study of 51 subjects in order to prepare for our FDA clinical Trial planned for later this fall.  See details below. 
If you would like to see the results of the Pilot Study, please email me and I will forward them to you. 
Clear Solutions for Reading LLC (“CSR”), working in conjunction with ChromaGen Vision LLC, carried out a Pilot Study in Tampa, Florida in May and June of 2014. The principals of CSR are Jeanne Howes PhD, an educational psychologist, who has been practicing for twenty-five years with an emphasis on children and families, and Edward Huggett Jr, OD, who is a licensed optometrist with a twenty-five year practice with an emphasis on binocular vision.
Goals of the Pilot Study.  ChromaGen Vision was seeking to determine if a student with a reading problem who uses ChromaGen Lenses would receive benefits in the following four areas:

Increase in Reading Speed
Increase in Reading Comprehension
Decrease in Word Movement Symptoms that cause problems with reading
Decrease in the Vision Related Issues that cause the “nagging symptoms” of headaches, nausea, fatigue, eyestrain, and loss of place when reading. 


Create a Life You Want to See

August 26, 2014

The following is by Lauren Tappan,

When some people get a diagnosis of macular degeneration or other retinal diseases, it can be quite a shock. It usually takes a long time to understand, deal with, and readjust your life to these new dimensions. Some people start to lose interest in their life situation and their vision begins to diminish. A friend of mine once said, “Create a life you want to see.” This seems to be a helpful phrase to remember when first dealing with sight loss. Developing a sense of curiosity about your life and people surrounding you can help to maintain good vision.
Remember, “create a life you want to see.”

It’s Time to Go Mobile

August 26, 2014

The following is by Lauren Tappan, It is a quote from the AI Squared blog.

Who would have thought a decade ago that a smartphone or tablet device with a non-tactile touch screen could be operated completely non-visually? With Apple’s VoiceOver and Google Android’s TalkBack as the major players in touch-based screen reading, one can slide, swipe, and tap on the screen to make a phone call, check the weather, look at your calendar, or even play a game without seeing what’s on the screen. There’s not a lot of memorization or training required because the screen reader tells you what you’ve selected and then may give you hints on what to do next. Zooming in is also an option if you have partial sight, but I use this only occasionally to view a picture or familiarize myself with an app. On small touch screens, I find zooming is just not an efficient way to navigate around.

On the Apple iOS side, which is all I’m familiar with, you can pretty much bet that you’ll have complete access to all the native apps that come pre-installed on the device using VoiceOver. For example, when sliding your finger over a button, VoiceOver will tell you what that button is. Now you can double tap anywhere on the screen in order to select the button that was just announced. As for third party apps that you download for free or purchase from the iTunes store, it’s anyone’s guess whether you’ll have VoiceOver access to all the buttons and features within the app. Then there’s the question of whether updates to the app will decrease the accessibility. For the sighted, updating is usually a good idea, but VoiceOver users tend to hesitate or simply cross their fingers and hope for the best because it’s not possible to “go back” and download a previous version from the iTunes store.

The notes and reviews for the app in the iTunes store or the AppleVis website might give you some clue regarding the app’s level of accessibility, so it’s always good to check before you download. As an example, when a developer doesn’t label a button, you may come across the ever-helpful announcement of “button” for some (or all) buttons. While the user has the ability to label buttons, this may be futile if the app keeps changing in subsequent updates. The best solution for developers is to use the tools that Apple gives them to make their app accessible. Depending on the app, this may take little to no extra effort at all on the developer’s part.

At any rate, the National Federation of the Blind (NFB) is resolved to encourage Apple to not accept apps into the iTunes store until they are accessible. Apple is adding even more features in its developer toolkit to make it pretty effortless to do so. So in the Apple world, I suspect the frustration of purchasing an app that you can’t effectively use with VoiceOver will become a thing of the past in the next few years.

If you still haven’t jumped into the mobile market due to your low vision, or can’t decide which solution is right for you, here are some articles that might help:


Telescopic Eyeglasses

August 9, 2014

Working with a manufacturer of dental and surgical optical devices, CraftOptics has designed a set of telescopic eyeglasses for the craft trade. They provide precision magnification with a wide field of view. There’s no distortion or fuzzy edges and our telescopes provide easy viewing both inside and outside the magnified field. Designed to allow comfortable working distances for crafts and hobbies to prevent back and neck soreness and eye strain. Adjustable working angle lets you easily choose and change your position. Very lightweight at 48 grams with a bifocal prescription installed!


Seeing Eye Shoes

August 9, 2014

Totally New Navigation Assistive Device

Indian wearable tech startup Ducere Tech has created smart shoes called Lechal that can give the wearer directions without needing to look at a smartphone. Lechal translates as “take me there” in Hindi.

Lechal shoe

The user enters her destination into the Lechal app using Google Maps or a similar navigation app. From this point on, the company claims, she no longer needs to look at her phone. The app connects via Bluetooth to a module that slides into the back of the shoe. The right or left shoe then buzzes depending on which direction the user should turn.

For more info:



Treatments for Stargardt’s

August 3, 2014

Examining various methods and treatments currently in clinical and pre-clinical stages .

Pharmacologic, gene therapy, and stem cell therapy approaches to Stargardt’s disease are currently in clinical and pre-clinical development, said Hendrik P.N. Scholl, MD, MA.  The FDA recommended a prospective study on the natural history of Stargardt’s disease, he continued. To this end, The Natural History of the Progression of Atrophy Secondary to Stargardt’s Disease (ProgStar) Study was developed.

Medical therapy

Several compounds have shown promise as potential medical therapy of Stargardt’s disease, Dr. Scholl said.

“Toxic A2E accumulates in every retina, but at a much higher rate in Stargardt’s disease retinas.

In addition, deuterated vitamin A are may help slow the accumulation of A2E by blocking its formation downstream the visual cycle, Dr. Scholl explained. The effects of deuterated vitamin A are currently in a phase Ia trial.

Gene therapy

Gene therapy is also being developed and there is an active clinical trial in phase Ib. The program is being sponsored by Sanofi-Fovea. Pre-clinical data had been convincing to show that delivering the healthy gene to the photoreceptor had a significantly positive impact on A2E accumulation in a mouse model of the disease, Dr. Scholl said.

Stem cell therapy

Stem cell therapy is yet another option for the treatment of Stargardt’s disease that is also currently being studied, Dr. Scholl added.

From the Advanced Cell Technology trial there is a preliminary report on stem cell therapy in age-related macular degeneration and Stargardt’s disease.

– See more at: